The interplay between drugs and cell metabolism is a key factor in determining both compound 24 potency and toxicity. In particular, how and to what extent transmembrane transporters affect drug 25 uptake and disposition is currently only partially understood. Most transporter proteins belong to 26 two protein families: the ATP-Binding Cassette (ABC) transporter family, whose members are 27 often involved in xenobiotic efflux and drug resistance, and the large and heterogeneous family of 28
Introduction 45 46 The role of cellular metabolism in determining the potency and distribution of drugs is increasingly 47 in what represents, to our knowledge, the first work applying this type of analysis to this group of 91 genes. list was searched against PubChem (Kim et al., 2016) in order to systematize names. ƒA list of 106 FDA-approved drugs was obtained from the organization's website. Network visualization was 107 done using Cytoscape (Shannon et al., 2003) . 108 109
All data corresponding to the Genomics of Drug Sensitivity in Cancer (GDSC) dataset (drug 110 sensitivity, expression, copy number variations, single nucleotide variants, compounds, cell lines) 111
were obtained from the original website of the project http://www.cancerrxgene.org/downloads as 112
of September 2016. Drug sensitivity and transcriptomics data were used as provided. Genomics 113 data were transformed into a binary matrix of genomic alterations vs cell lines, where three 114 different modifications for every gene were considered using the original source files: 115 amplifications (ampSLCx), deletions (delSLCx) and variants (varSLCx). An amplification was 116 annotated if there were more than two copies of at least one of the alleles for the gene of interest, 117
and a deletion if at least one of the alleles was missing. Single nucleotide variants were filtered in 118 order to exclude synonymous SNVs as well as nonsynonymous SNVs predicted not to be 119 deleterious by either SIFT (Ng and Henikoff, 2001) Expression values for all genes in the dataset (17419 genes in total) were used as input features. 126
For each compound, the analysis was iterated 50 times over 10-fold cross validation. At each cross 127 validation, features were ranked based on their frequency of appearance (number of times a feature 128 has non zero coefficient for 100 default lambda possibilities). We then averaged the ranking across 129 the 500 runs (50 iterations x 10 CV) in order to obtain a final list of genes associated to each 130 compound. In this context, the most predictive gene for a certain drug does not necessarily have 131
an average rank of one, even though its final rank is first. We collected data from public repositories as well as relevant publications to define the current 161 knowledge on transport of chemical compounds by members of the SLC and ABC protein classes.
162
A total of 493 compounds linked to 107 transporters were retrieved, which altogether formed a 163 single large network with a few other smaller components ( Fig.1 , Table S1 ).
165
Within the largest network and in agreement with previous reports (Nigam, 2015) , as members of the SLC15 family (SLC15A1 and SLC15A2, which share 22 compounds), involved 179
in the transport of beta-lactam antibiotics and peptide-mimetics (Smith et al., 2013) . In contrast to 180 these cases, other transporters appear related to one or only a few compounds. One such case is 181 SLC35F2, whose only reported substrate to date is the anti-cancer drug YM155 (sepantronium 182 bromide) (Winter et al., 2014) . Finally, while most chemical compounds appear linked to one or 183 two transporters, a few others show higher connectivities (Fig.1C) . A well-known example, 184 methotrexate is transported by more than 20 different SLC and ABCs, including some belonging 185
to families not commonly involved in drug transport, such as the folate carriers SLC19A1 and 186 SLC46A1. 187 188
Transporter expression landscape in cancer cell lines 189 190
The GDSC dataset contains expression data for 371 SLCs and 46 ABCs across a panel of ~1000 191
cell lines of different tissue origin. Each of these cell lines effectively express between 167 and 192 255 transporters, with a median value of 195 ( Fig.2A ). Although all together they cover almost 193 the whole transporter repertoire (414/417), the distribution is clearly bimodal, with a common set 194 of ~130 transporters expressed in at least 900 cell lines and a more specific set of ~140 expressed 195 in less than 100 ( Fig.2B ). Among the most commonly expressed transporters, we find several 196 members of the SLC25 (mitochondrial carriers) and SLC35 (nucleoside-sugars transporters) sub-197 families, the two largest among SLCs, as well as several members of the SLC39 family of zinc 198
transporters. On the other end, many members of the SLC22 family, a large and well known group 199 of proteins involved in the transport of drugs, as well as the SLC6 family, a well-studied family of 200 neurotransmitter transporters, show a more specific expression pattern. As for ABCs, it is worth 201
highlighting that subfamilies A and C present half of their members in the set of transporters of 202 specific expression, while subfamily B has members in both sets.
204
When looking at actual expression values across the panel, some of the commonly expressed 205
transporters coincide with those of highest expression ( Fig.2C ). The most extreme cases are 206 SLC25A5, SLC25A3, SLC25A6 and SLC38A1, which present very similar maximum and median 207 values across the cell line panel. On the contrary, other transporters such as SLC26A3, SLC17A3, 208 or SLC38A11 present a much wider range of expression, being amongst the highest expressed in 209 some cell lines but completely absent from others. 210 211
Finally, substantial differences become apparent when considering transporter expression patterns 212
according to the tissue of origin of the GDSC cancer cell lines ( Fig.2D ), Cell lines belonging to 213 the hematopoietic (blood) lineage, which includes leukemias, lymphomas and myelomas, present 214 the largest proportion of transporters with highest average expression values (28%), as indicated 215
by Z-score, followed by cancer cell lines belonging to skin, kidney and the digestive system. This 216
indicates a broad spectrum of transporters being present in cell lines of these tissue origins. 217
Interestingly, kidney cell lines also present the largest number of transporters with low expression 218 values, pointing to a very wide range of expression and high specificity in those cells. 219 220
LASSO regression shows importance of SLC genes across whole genome 221 222
We investigated the importance of SLC and ABC transporters for drug response by applying 223 regularized linear regression on the GDSC dataset. To this end, we first built LASSO models of 224 sensitivity to each compound based on genome-wide gene expression levels (17419 genes in total) 225 (Tibshirani, 1996) , and then looked for cases where a transporter ranked as the top (first) predictor 226 (see Methods). The choice of the LASSO method is motivated by its ability to shrink a large 227 number of coefficients to zero, ideal for models that make use of thousands of predictors. 228
Moreover, being a linear regression method, it can account for both positive and negative 229 interactions (i.e. resistance and sensitivity, for example by export and import in the case of a 230 transporter), thus increasing the interpretability of the results. The decision to focus exclusively on 231 the top predictor is supported by a literature search. Indeed, the average number of PubMed 232 publications containing both the drug and the gene name was over 40 in the case of top predictors, 233
falling down to below 10 for the ones ranked second (Fig.S1 ).
235
Consistent with their well-characterized role as drug-transporters, the multi-drug resistance pump 236 ABCB1, as well as ABCG2, were the main predictors of resistance to a large number of drugs 237
( Table 1A) . More interestingly, several compounds had an SLC as their best predictor (Table 1B) . 238 Among them, and in concordance with previous expression-sensitivity data ( In order to further explore SLC and ABC involvement in drug response, we decided to build new 256 predictive models based on transporter molecular data only. By removing the effect of other genes 257
in the models, we can prioritize compounds that show a stronger dependency on transporters, as 258 well as to analyze potential cooperative interactions among them. Given the smaller amount of 259 predictors in this case, we used Elastic Net regression, a generalization of the LASSO that 260 overcomes some of its limitations and that has already been applied in similar contexts ( We considered different predictors to build the models: genomics (Copy Number Variations and 265
Single Nucleotide Variants), transcriptomics (gene expression) and a combination of both. Among 266 these, gene expression resulted to be most predictive, in agreement with previous reports (Aydin 267 et al., 2014)( Fig.3A) . 139 (53%) of the 265 drugs included in the dataset had predictive models 268
with a CI higher than 0.60, and 36 (14%) higher than 0.65 (Fig.3B ). For those drugs, we then 269
ranked genes based on their frequency of appearance in the cross-validated models (indicative of 270 the robustness of the association) and their average weight (indicative of the strength of the 271 association as well as its direction). In this context increased levels of transporter expression could 272 therefore be associated with either sensitivity or resistance to the drug, for example through its 273 uptake or efflux, respectively (Fig.3C ). Among the top ranked transporter-drug associations, we 274
identified several known cases of drug transport. For instance, the strongest sensitivity association 275
with sepantronium bromide (YM155) corresponded again to SLC35F2. Similarly, the strongest 276 resistance association for this drug was ABCB1, which includes YM155 among its many 277
substrates ( was methotrexate, for which the folate transporter SLC19A1, known to mediate its import (Zhao 279 et al., 2011), ranked second for sensitivity association (Table S3 ). 280 281
Two major patterns are apparent in the set of top-ranking associations: genes showing similar 282
profiles of resistance or sensitivity across several different and unrelated compounds as well as 283 groups of genes showing a similar profile in relation to a functionally related class of drugs ( Fig.  284  3C) .
286
A prototypical case of the first pattern is ABCB1, which is associated with resistance phenotypes 287
to several compounds (Fig.3D ). Together with the aforementioned YM155, resistance not previously associated compounds such as ZG-10 (a JNK1 inhibitor), the CDK2/5/7 inhibitor 291
PHA-793887 and the broad kinase inhibitor WZ3105. Similar to ABCB1, other transporters 292
showed multiple resistance and sensitivity associations to different compounds, particularly 293
kinases and chromatin-related enzymes. Two of these "hubs" were SLC12A4/KCC1, a potassium-294 chloride cotransporter involved in cell volume homeostasis (Arroyo et al., 2013), and SLC35D2, 295
an activated sugar transporter localized in the Golgi (Song, 2013) . 296 297
As an example of the second class of associations, some of the best models were achieved for 298 compounds belonging to the MEK inhibitor drug class (Trametinib, Selumetinib, Refametinib, CI-299 1040, PD-0325901, (5Z)-7-oxozeaenol), which showed very similar patterns, with sensitivity 300 associated to SLC45A2, SLC27A1, SLC20A1, and SLC22A15 (Fig.3E ). SLC45A2 has been 301 related to melanin synthesis and it is highly expressed in melanomas (Park et al., 2017), a cancer 302 type sensitive to MEK inhibitors. Interestingly, SLC20A1/PiT1, a sodium-dependent phosphate 303
transporter (Olah et al., 1994) , was previously shown to regulate the ERK1/2 pathway 304 independently of phosphate transport in skeletal cells (Bon et al., 2018). SLC27A1, a long-chain 305 fatty acid transporter, and SLC22A15, an orphan member of the well-known family of cationic 306 transporters involved in the transport of different compounds, were not previously associated with 307 this drug class. 308 309
Finally, we also observed a strong sensitivity relationship between expression levels of the amino 310 acid transporter SLC7A5/LAT1 and the Her2 and EGFR kinase inhibitors Afatinib, Gefitinib and 311 Bosutinib (Fig. 2C) , consistent with previously published data (Timpe et al., 2015) . relationships revealed that only a fifth of the more than 500 SLCs and ABCs have been described 321
to be involved in the transport of drugs. These transporters appear to be very unevenly distributed, 322
with some genes and families considerably more represented and better connected than others 323 (Fig.1) . This is the case for several members of the ABCB, ABCC, SLCO and SL22 sub-families.
324
Similarly, while compounds such as methotrexate are linked to more than 20 transporters, most 325
drugs are connected to only one. 326 327
To further expand this network, we took advantage of the expression and drug sensitivity data 328 available within the GDSC project. We started by characterizing the expression patterns of SLCs 329
and ABCs in the GDSC panel of ~1000 cancer cell lines, covering thirteen different tissues of 330 origin (Fig.2) . Roughly 80% of SLCs and 90% of ABCs were included in the datasets and we now extended these results to a much more comprehensive set of cell lines while implementing 341 regularized linear regression approaches (Elastic Net and LASSO regression). We identify a large 342 set of drug-transporter associations roughly split between sensitivity and resistance relationships 343 (Tables 1A and 1B, Fig.3) . Known associations involving, for example, ABCB1 expression levels 344
with increasing resistance to several unrelated compounds as well as known interactions such as 345 the associations between antifolates and SLC19A1 or YM155 and SLC35F2 were clearly 346
identified. Interestingly, we also observed cases were, similarly to ABCB1, a single gene was 347 associated with several compounds, possibly as a result of an alteration of the general metabolic 348 state of the cell. We also observed the opposite scenario, with several genes associated with a 349
functionally related class of compounds as in the case of the MEK inhibitors and the genes 350 SLC45A2, SLC27A1, SLC20A1, and SLC22A15. To our knowledge, no transporter has so far 351 been identified for any member of this class of compounds, and while the association with the 352 skin-specific SLC45A2 transporter is likely the result of the high sensitivity of melanoma cell lines 353 to these drugs, other associations are more difficult to interpret.
355
We propose the gene list reported here as a means of prioritizing transporters that could explain 356 the transport and pharmacodynamics of the associated compounds. While in many cases these 357 associations could be due to indirect effects, such as a change in the metabolic state of the cells 358 that renders them more sensitive or resistant to a compound, some might correspond to actual 359 import or export processes. Further validation, for example modulating the expression levels of 360 the transporters or by transport assays, will be necessary in order to confirm and distinguish such 361 different scenarios. Finally, the power of the analysis could also be increased by larger datasets, 362
for instance including additional compounds, as well as by orthogonal or more accurate 363 measurements. Availability of such pharmacogenomics datasets will be of critical importance for 364 the further identification and characterization of transporter-drug associations. In conclusion, we 365 provide here an overview of the known ABC-and SLC-based drug transport relationships and 366 expand this with an in silico-derived ranking of transporter-drug associations, identifying several 367 novel and potential interesting interactions that could affect the pharmacodynamics and 368 pharmacokinetics of a large set of clinically relevant compounds. 369 370
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